Cargando…

Congenital disorders of glycosylation: narration of a story through its patents

Congenital disorders of glycosylation are a group of more than 160 rare genetic defects in protein and lipid glycosylation. Since the first clinical report in 1980 of PMM2-CDG, the most common CDG worldwide, research made great strides, but nearly all of them are still missing a cure. CDG diagnosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monticelli, Maria, D’Onofrio, Tania, Jaeken, Jaak, Morava, Eva, Andreotti, Giuseppina, Cubellis, Maria Vittoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466741/ https://www.ncbi.nlm.nih.gov/pubmed/37644541 http://dx.doi.org/10.1186/s13023-023-02852-w

Ejemplares similares

How to find and diagnose a CDG due to defective N-glycosylation
por: Lefeber, Dirk J., et al.
Publicado: (2011)

Public and patient involvement in needs assessment and social innovation: a people-centred approach to care and research for congenital disorders of glycosylation
por: de Freitas, Cláudia, et al.
Publicado: (2017)

Congenital Disorders of Glycosylation: A Multi-genetic Disease Family with Multiple Subcellular Locations
por: Jaeken, Jaak
Publicado: (2020)

β-Glucose-1,6-Bisphosphate Stabilizes Pathological Phophomannomutase2 Mutants In Vitro and Represents a Lead Compound to Develop Pharmacological Chaperones for the Most Common Disorder of Glycosylation, PMM2-CDG
por: Monticelli, Maria, et al.
Publicado: (2019)

Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation
por: Andreotti, Giuseppina, et al.
Publicado: (2013)

Stakeholders’ views on drug development: the congenital disorders of glycosylation community perspective
por: Monticelli, Maria, et al.
Publicado: (2022)

SRD5A3 defective congenital disorder of glycosylation: clinical utility gene card
por: Jaeken, Jaak, et al.
Publicado: (2020)

Conformational Response to Ligand Binding in Phosphomannomutase2: INSIGHTS INTO INBORN GLYCOSYLATION DISORDER
por: Andreotti, Giuseppina, et al.
Publicado: (2014)

Looking for protein stabilizing drugs with thermal shift assay
por: Andreotti, Giuseppina, et al.
Publicado: (2015)

Systematic Review: Drug Repositioning for Congenital Disorders of Glycosylation (CDG)
por: Brasil, Sandra, et al.
Publicado: (2022)

Congenital disorders of glycosylation (CDG): state of the art in 2022
por: Francisco, Rita, et al.
Publicado: (2023)

Nutritional Therapies in Congenital Disorders of Glycosylation (CDG)
por: Witters, Peter, et al.
Publicado: (2017)

Defective IGF-1 prohormone N-glycosylation and reduced IGF-1 receptor signaling activation in congenital disorders of glycosylation
por: Di Patria, Laura, et al.
Publicado: (2022)

Why does SARS-CoV-2 hit in different ways? Host genetic factors can influence the acquisition or the course of COVID-19
por: Monticelli, Maria, et al.
Publicado: (2021)

Platelets and Defective N-Glycosylation
por: Mammadova-Bach, Elmina, et al.
Publicado: (2020)

Taming molecular flexibility to tackle rare diseases
por: Cubellis, Maria Vittoria, et al.
Publicado: (2015)

A Community-Led Approach as a Guide to Overcome Challenges for Therapy Research in Congenital Disorders of Glycosylation
por: Francisco, Rita, et al.
Publicado: (2022)

The road to successful people-centric research in rare diseases: the web-based case study of the Immunology and Congenital Disorders of Glycosylation questionnaire (ImmunoCDGQ)
por: Francisco, Rita, et al.
Publicado: (2022)

CDG Therapies: From Bench to Bedside
por: Brasil, Sandra, et al.
Publicado: (2018)

New Insights into Immunological Involvement in Congenital Disorders of Glycosylation (CDG) from a People-Centric Approach
por: Francisco, Rita, et al.
Publicado: (2020)

The Analysis of Variants in the General Population Reveals That PMM2 Is Extremely Tolerant to Missense Mutations and That Diagnosis of PMM2-CDG Can Benefit from the Identification of Modifiers
por: Citro, Valentina, et al.
Publicado: (2018)

Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations
por: Liguori, Ludovica, et al.
Publicado: (2020)

Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type I
por: Guillard, Mailys, et al.
Publicado: (2011)

CAMLG-CDG: a novel congenital disorder of glycosylation linked to defective membrane trafficking
por: Wilson, Matthew P, et al.
Publicado: (2022)

Identification and analysis of conserved pockets on protein surfaces
por: Cammisa, Marco, et al.
Publicado: (2013)

Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones
por: Cammisa, Marco, et al.
Publicado: (2013)

A thermodynamic assay to test pharmacological chaperones for Fabry disease()
por: Andreotti, Giuseppina, et al.
Publicado: (2014)

Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2
por: Andreotti, Giuseppina, et al.
Publicado: (2015)

Mannose treatment improves immune deficiency in mannose phosphate isomerase–congenital disorder of glycosylation: case report and review of literature
por: De Graef, Diederik, et al.
Publicado: (2022)

Drug repositioning can accelerate discovery of pharmacological chaperones
por: Hay Mele, Bruno, et al.
Publicado: (2015)

Patient reported outcomes for phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG): listening to what matters for the patients and health professionals
por: Pascoal, C., et al.
Publicado: (2022)

A rare cause of infantile achalasia: GMPPA‐congenital disorder of glycosylation with two novel compound heterozygous variants
por: Geiculescu, Irina, et al.
Publicado: (2022)

Successful heart transplantation in an infant with phosphoglucomutase 1 deficiency (PGM1‐CDG)
por: Altassan, Ruqaiah, et al.
Publicado: (2022)

Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study
por: Andreotti, Giuseppina, et al.
Publicado: (2010)

Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease
por: Monticelli, Maria, et al.
Publicado: (2023)

Propeptide glycosylation and galectin‐3 binding decrease proteolytic activation of human proMMP‐9/progelatinase B
por: Boon, Lise, et al.
Publicado: (2018)

A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG
por: Citro, Valentina, et al.
Publicado: (2017)

The story of O-glycosylation
por: Short, Ben
Publicado: (2010)

Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones
por: Monticelli, Maria, et al.
Publicado: (2022)

Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
por: Iyer, Sangeetha, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lavk8l1hdl8jkpij8kqk08fq5v